title: Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study.
abstract: BACKGROUND
  We sought to investigate whether higher concentrations of resistin and lower concentrations of adiponectin relate to incident atrial fibrillation (AF) and whether this association is mediated by AF risk factors and inflammation. Resistin and adiponectin are adipokines that have been associated with multiple known risk factors for AF including diabetes, obesity, inflammation, and heart failure.
  
  
  METHODS
  We studied the relations between circulating concentrations of both adipokines and incident AF in participants of the Framingham Offspring Study.
  
  
  RESULTS
  Participants (n = 2,487) had a mean age of 61 ± 10 years, and 54% were women. During a mean follow-up of 7.6 ± 2.0 years, 206 (8.3%) individuals (96 women) developed incident AF. Plasma resistin concentration was significantly associated with incident AF (multivariable-adjusted hazard ratio [HR] 1.17 per SD [0.41 ng/mL] of natural logarithmically transformed resistin, 95% CI 1.02-1.34, P = .028). The resistin-AF association was attenuated after further adjustment for C-reactive protein (HR per SD increase resistin 1.14, 95% CI 0.99-1.31, P = .073). Adiponectin concentrations were not significantly associated with incident AF (multivariable-adjusted HR of 0.95 per SD [0.62 μg/mL] of logarithmically transformed adiponectin, 95% CI 0.81-1.10, P = .478).
  
  
  CONCLUSIONS
  In our community-based longitudinal study, higher mean concentrations of resistin were associated with incident AF, but the relation was attenuated by adjustment for C-reactive protein. We did not detect a statistically significant association between adiponectin and incident AF. Additional studies are needed to clarify the potential role of adipokines in AF and mechanisms linking adiposity to AF.
authors.affiliation: Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, USA.
authors.forename: Michiel
authors.initials: M
authors.lastname: Rienstra
authors.forename: Jenny X
authors.initials: JX
authors.lastname: Sun
authors.forename: Steven A
authors.initials: SA
authors.lastname: Lubitz
authors.forename: David S
authors.initials: DS
authors.lastname: Frankel
authors.forename: Ramachandran S
authors.initials: RS
authors.lastname: Vasan
authors.forename: Daniel
authors.initials: D
authors.lastname: Levy
authors.forename: Jared W
authors.initials: JW
authors.lastname: Magnani
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Sullivan
authors.forename: James B
authors.initials: JB
authors.lastname: Meigs
authors.forename: Patrick T
authors.initials: PT
authors.lastname: Ellinor
authors.forename: Emelia J
authors.initials: EJ
authors.lastname: Benjamin
mesh_terms: D052242:Adiponectin / Q000097:blood*; D001281:Atrial Fibrillation / Q000097:blood / Q000453:epidemiology* / Q000401:mortality; D015415:Biomarkers / Q000097:blood; D003153:Community Health Services; D004739:England; D005260:Female; D006801:Humans; D015994:Incidence; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D052243:Resistin / Q000097:blood*; D012307:Risk Factors
chemical_list: D052242:Adiponectin; D015415:Biomarkers; D052243:Resistin